Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI-825 in Advanced Solid Tumors
NCT06299761Phase 1Terminated
- Sponsor
- Boundless Bio
- Start
- Mar 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BBI-825 in solid tumor, sponsored by Boundless Bio. Primary endpoints: Treatment Emergent Adverse Events, Maximum Tolerated Dose and 1 more. Started Mar 2024; status: terminated.
02
Drugs
BBI-825
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06299761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06299761.